Studies have shown that Cetuximab, β-elemene or Bromelain promoted ferroptosis in KRAS mutant CRC cells, which is via inhibition of Nrf2/HO-1 pathway or epithelial-mesenchymal transformation [55,56,57]. This evidence concerns the gene KRAS and colorectal carcinoma.